Body mass determines clinical outcomes of antihypertensive treatment Michael A. Weber Clinical Trials Report Pages: 352 - 352
Prehypertension: A possible target for antihypertensive medication Shawna D. NesbittStevo Julius OriginalPaper Pages: 356 - 361
Importance of various methods of blood pressure measurement in clinical trials Paolo Palatini OriginalPaper Pages: 362 - 369
Mechanism of differential effects of antihypertensive agents on serum lipids Robert D. Brook OriginalPaper Pages: 370 - 377
The promise of selective aldosterone receptor antagonists for the treatment of hypertension and congestive heart failure Asim HameediHal L. Chadow OriginalPaper Pages: 378 - 383
Vasopeptidase inhibition: A new direction in cardiovascular treatment Jordan R. AsherAllen J. Naftilan OriginalPaper Pages: 384 - 391
Angiotensin converting enzyme inhibitors: Are they preferred first-line therapy? Stephen P. Glasser OriginalPaper Pages: 392 - 397
Evidence-based treatment of hypertension James A. Schoenberger Clinical Trials Report Pages: 398 - 398
Therapeutic trials comparing angiotensin converting enzyme inhibitors and Angiotensin II receptor blockers William J. Elliott OriginalPaper Pages: 402 - 411
Coronary heart disease prevention as the primary goal in contemporary trials in the treatment of hypertension Peter S. Sever OriginalPaper Pages: 418 - 420